Bcn Peptides S.a.

Josep Farrera-Sinfreu

Berta Ponsati Obiols

Antonio Parente Duena

Antonio Vicente Ferrer Montiel

Antonio Parente Dueña

Jimena Fernández Carneado

Jimena Fernandez Carneado

Leslie Matalonga Borrel

Laura Gort Mas

Roberto Pascual Martínez

Antonia Ribes Rubió

Natalia Navarro Barea

Lucas Moreno Martin-Retortillo

Jose Sanchez De Toledo Codina

Soledad Gallego Melcon

Carla Molist Munoz

Mariona Valles-Miret

Anna Almazan-Moga

Berta Ponsati

Antonia Ribes Rubio

Roberto Pascual Martinez

The invention relates to cortistatin analogues and their uses. The compounds of the invention are peptide ligands with potential application in the diagnosis, prevention or therapy of those pathologies where receptors capable of binding to cortistatin, specific or shared with other molecules such as somatostatin and/or ghrelin (GHSR), are expressed, being in addition more stable in serum than cortistatin.

Cortistatin analogues for the treatment of inflammatory and/or immune diseases

The invention provides a therapy for lysosomal storage diseases and glycogenosis by treatment with compounds that promote exocytosis, preferably lysosomal exocytosis. The treatment of cells from patients affected by different lysosomal storage disorders with exocytosis activating compounds leads to a decrease in the accumulation of toxic substrate in the lysosomes, thus allowing the treatment, prevention and relief of the symptoms of many lysosomal storage disorders.

Bicalutamide analogs or (S)-bicalutamide as exocytosis activating compounds for use in the treatment of a lysosomal storage disorder or glycogenosis

Growing community of inventors

Tírvia, Spain

Josep Farrera-Sinfreu